Calvin Q Pan, Nancy Reau
The landscape of liver disease management continues to evolve, with notable advancements in non-invasive diagnostics, understanding of perioperative risk, new therapies for cirrhotic complications, metabolic dysfunction-associated steatotic liver disease (MASLD), and alcohol-associated liver disease (ALD), as well as screening for hepatocellular carcinoma (HCC) and the management of special populations such as mothers with hepatitis B.
Jimmy Che-To Lai, Lilian Yan Liang, Grace Lai-Hung Wong

Liver fibrosis is the common pathway from various chronic liver diseases and its progression leads to cirrhosis which carries a significant risk for the development of portal hypertension-related complications and hepatocellular carcinoma.
Sameer Bhalla, Brendan Mcquillen, Edward Cay, Nancy Reau

The prevalence of liver disease is rising and more patients with liver disease are considered for surgery each year
Jasleen Singh, Mark Ebaid, Sammy Saab

Cirrhosis with complications of liver decompensation and hepatocellular carcinoma (HCC) constitute a leading cause of morbidity and mortality worldwide.
Shi OuYang, Yawen Geng, Gongqin Qiu, Yueying Deng, Haitao Deng, Calvin Q Pan

Postpartum elevation of alanine aminotransferase (ALT) in mothers with chronic hepatitis B (CHB) presents a significant clinical challenge. However, the existing literature demonstrates inconsistencies regarding its incidence and predictors in mothers infected with the hepatitis B virus (HBV).
Calvin Q Pan, Andrew J Park, James S Park

Achieving a sustained virologic response (SVR) through direct-acting antivirals for hepatitis C virus (HCV) infection significantly reduces the long-term risk of hepatocellular carcinoma (HCC), particularly in patients with advanced fibrosis (F3) or cirrhosis (F4).
Taizo Mori, Sachiyo Yoshio, Eiji Kakazu, Tatsuya Kanto

Non-alcoholic fatty liver disease, recently renamed metabolic dysfunction-associated steatotic liver disease (MASLD), is a complex multifactorial disease that progresses from steatohepatitis (MASH) to liver cirrhosis and liver cancer. Recent research has revealed that crosstalk between innate immune cells and hepatic parenchymal and non-parenchymal cells is involved in the pathogenesis of liver disease in MASLD/MASH.
Ahmad Anouti, Thomas A Kerr, Mack C Mitchell, Thomas G Cotter

Alcohol-associated liver disease (ALD) is a significant global health challenge, encompassing a spectrum from steatotic liver disease to cirrhosis and alcohol-associated hepatitis, and contributed to 25% of global cirrhosis deaths in 2019.
Anthony Kityo, Sang-Ah Lee

Binge drinking (BD) has been associated with elevated liver enzymes, but the joint association of BD and adiposity with liver enzymes is understudied.
Zixuan Li, Xiaoying Wu, Zebin Chen, Xiuqing Wei, Weiqing Chen

Recent studies have found that thyroid function may be associated with the occurrence and development of advanced liver fibrosis in patients with metabolic dysfunction-associated fatty liver disease (MAFLD).
Fateh Bazerbachi, Serge Baroud, Michael J Levy, Daniel B Maselli, Eric J Vargas and others

Visceral fat represents a metabolically active entity linked to adverse metabolic sequelae of obesity. We aimed to determine if celiac artery mesenteric fat thickness can be reliably measured during endoscopic ultrasound (EUS), and if these measurements correlate with metabolic disease burden.